Business Context and Reporting Period
Company: R&R Acquisition VI, Inc. (Note: The filing metadata references ADMA BIOLOGICS, INC., but the document text explicitly identifies the registrant as R&R Acquisition VI, Inc., a Delaware corporation).
Reporting Period: Fiscal year ended June 30, 2009.
Business Model: The Company is a "blank check" shell company and a development-stage enterprise. It has no specific business plan other than to investigate and acquire a target company to achieve the advantages of being a publicly held corporation. It has no employees, no operating history, and no revenues.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20,009) | $(24,891) |
| Total Operating Expenses | $20,020 | $24,916 |
| Cash and Cash Equivalents | $8,688 | $2,647 |
| Working Capital | $(2,820) | $(13,311) |
| Total Assets | $8,688 | $2,647 |
| Total Liabilities | $11,508 | $15,958 |
| Stockholders' Deficit | $(2,820) | $(13,311) |
Liquidity: The Company relies on capital contributions from stockholders and management to fund operations. As of June 30, 2009, cash on hand was $8,688. The Company anticipates this is sufficient for the next 12 months but cannot guarantee future funding availability.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $4,900 (19.6%) from $24,916 in 2008 to $20,020 in 2009. This reduction is attributed to lower professional and administrative fees.
- Net Loss Improvement: Net loss decreased from $(24,891) in 2008 to $(20,009) in 2009, consistent with the reduction in expenses.
- Cash Position: Cash and cash equivalents increased by $6,041, driven by a $30,500 capital contribution from a stockholder during the fiscal year.
- Liabilities: Accrued expenses decreased from $15,958 to $11,508, improving the working capital deficit.
Outlook, Risks, and Management Commentary
Outlook: The Company's sole objective for the next 12 months is to locate a suitable acquisition or merger candidate. It expects to have sufficient proceeds for only a single business combination unless additional financing is obtained. No definitive agreements with prospective targets exist.
Management Commentary: Officers (Arnold P. Kling and Kirk M. Warshaw) devote less than 10% of their time to the Company. They receive no regular compensation. Management believes cash on hand will satisfy requirements for the next 12 months but notes a lack of assurance regarding future funding.
Risks and Contingencies:
- Going Concern: The Company has no operating history or revenue. Success is entirely dependent on consummating a business combination.
- Competition: The Company faces significant competition from better-financed entities for potential acquisition targets.
- Conflicts of Interest: Management is involved with other blank check offerings, creating potential conflicts of interest.
- Dilution: Future mergers may result in substantial dilution to existing shareholders through the issuance of additional shares.
- Regulatory: There is a risk of being classified as an "investment company" under the Investment Company Act of 1940, which would incur significant compliance costs.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (ADMA BIOLOGICS, INC.) and the actual registrant (R&R Acquisition VI, Inc.).
- Confirm the status of the $30,500 capital contribution from R&R Investments VI, LLC (the 80% controlling shareholder).
- Assess the sustainability of the $8,688 cash balance against the $11,508 in accrued liabilities.
- Review the related-party office lease agreement with Kirk M. Warshaw, LLC ($500/quarter) for potential conflicts.
- Monitor for any announcements regarding a definitive business combination, as the company has no independent revenue stream.